| Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) (NCT05329545) | Mersana Therapeutics | 2022-06-23 |
| Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (NCT05092360) | Mural Oncology, Inc | 2022-01-10 |
| TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT05053750) | M.D. Anderson Cancer Center | 2021-12-14 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer (NCT04510584) | University Health Network, Toronto | 2021-07-16 |
| Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer (NCT05030246) | Peking University | 2021-07-14 |
| Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT04606914) | University of Alabama at Birmingham | 2021-05-27 |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (NCT04657068) | Artios Pharma Ltd | 2021-01-27 |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab (NCT04590326) | Regeneron Pharmaceuticals | 2020-12-08 |
| Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer (NCT04546373) | Grupo Español de Investigación en Cáncer de Ovario | 2020-09-30 |
| Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study (NCT04539327) | Grupo Español de Investigación en Cáncer de Ovario | 2020-07-29 |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients (NCT04227522) | North Eastern German Society of Gynaecological Oncology | 2020-06-08 |
| A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT04029909) | Lee's Pharmaceutical Limited | 2019-07-11 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (NCT03872947) | Toray Industries, Inc | 2019-04-26 |
| Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer (NCT03759587) | Takeda | 2018-12-28 |
| Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer (NCT03759600) | Takeda | 2018-12-26 |
| Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (NCT03393884) | Imunon | 2018-09-05 |
| A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03635489) | Hoffmann-La Roche | 2018-08-15 |
| Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer (NCT07648745) | Prof Gordon Jayson | 2018-05-14 |
| A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors (NCT03311334) | Sumitomo Pharma America, Inc. | 2017-12-14 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int (NCT03213964) | Masonic Cancer Center, University of Minnesota | 2017-10-19 |
| A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer (NCT03245892) | Memorial Sloan Kettering Cancer Center | 2017-08-04 |
| Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors (NCT03189108) | National Cancer Institute (NCI) | 2017-05-22 |
| Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab (NCT03093155) | Yale University | 2017-04-03 |
| Homologous Recombination Inquiry Through Ovarian Malignancy Investigations (NCT03159572) | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2017-03-28 |
| Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT02948426) | National Cancer Institute (NCI) | 2017-02-08 |
| The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors (NCT03507543) | Impact Therapeutics, Inc. | 2017-02-03 |
| Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery (NCT02884648) | M.D. Anderson Cancer Center | 2016-11-15 |
| A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer (NCT02737787) | Memorial Sloan Kettering Cancer Center | 2016-04-01 |
| Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (NCT02606305) | ImmunoGen, Inc. | 2016-03-02 |
| Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer (NCT02567253) | University Hospital, Ghent | 2016-03-01 |
| Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer (NCT02480374) | Imunon | 2015-09-01 |
| p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (NCT02435186) | Shenzhen SiBiono GeneTech Co.,Ltd | 2015-06-01 |
| Autologous OC-L Vaccine and Ovarian Cancer (NCT02452775) | Abramson Cancer Center at Penn Medicine | 2015-05-01 |
| Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer (NCT02278783) | University of Utah | 2015-03-01 |
| Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission (NCT02324439) | Southern Illinois University | 2015-03-01 |
| "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT01883297) | University Health Network, Toronto | 2015-01-01 |
| Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies (NCT01880996) | Sheba Medical Center | 2014-08-01 |
| GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer (NCT02012192) | Medical University Innsbruck | 2014-07-04 |
| Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT02121990) | Memorial Sloan Kettering Cancer Center | 2014-04-21 |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations (NCT01989546) | National Cancer Institute (NCI) | 2014-02-04 |
| PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer (NCT01899599) | Glycotope GmbH | 2013-09-01 |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01666444) | Celgene | 2012-10-31 |
| Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer (NCT01744821) | Northwestern University | 2012-10-01 |
| A Study LY2228820 for Recurrent Ovarian Cancer (NCT01663857) | Eli Lilly and Company | 2012-07-01 |
| DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer (NCT00603460) | University of Pennsylvania | 2012-01-01 |
| Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT01339650) | AbbVie (prior sponsor, Abbott) | 2011-05-06 |
| Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer (NCT01220154) | David O'Malley | 2011-04-28 |
| AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) (NCT01281254) | Amgen | 2011-04-18 |
| A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01312389) | Abramson Cancer Center at Penn Medicine | 2011-04-01 |
| Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer (NCT01196741) | University College, London | 2011-03-01 |
| Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer (NCT01312376) | Abramson Cancer Center at Penn Medicine | 2011-03-01 |
| Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers (NCT01237067) | National Cancer Institute (NCI) | 2011-02-07 |
| Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (NCT01296035) | Women and Infants Hospital of Rhode Island | 2011-02-01 |
| Phase II ABT-888 With Cyclophosphamide (NCT01306032) | National Cancer Institute (NCI) | 2011-01-12 |
| Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer (NCT01253681) | Amgen | 2010-11-01 |
| Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian (NCT01219777) | Ritu Salani | 2010-09-01 |
| Neoadjuvant Therapy for Ovarian Cancer (NCT01146795) | Jason D. Wright | 2010-05-17 |
| A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (NCT01570582) | Korean Gynecologic Oncology Group | 2010-03-01 |
| Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) (NCT00959582) | Merck Sharp & Dohme LLC | 2009-09-01 |
| Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer (NCT00928642) | Henry M. Jackson Foundation for the Advancement of Military Medicine | 2009-06-01 |
| Study of Paclitaxel in Patients With Ovarian Cancer (NCT00989131) | Oasmia Pharmaceutical AB | 2009-02-01 |
| Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00677079) | Sanofi | 2008-06-01 |
| Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod (NCT00799110) | Beth Israel Deaconess Medical Center | 2008-05-01 |
| Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00616941) | Ludwig Institute for Cancer Research | 2008-03-01 |
| A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients (NCT00526617) | AbbVie | 2007-08-01 |
| Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors (NCT00520013) | Dana-Farber Cancer Institute | 2007-08-01 |
| Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer (NCT00479817) | Amgen | 2007-07-05 |
| Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients (NCT00562003) | University of Alabama at Birmingham | 2007-06-01 |
| A Study of Chemotherapy Treatment for Patients With Ovarian Cancer (NCT00428610) | Eli Lilly and Company | 2007-02-01 |
| Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer (NCT00436215) | National Cancer Institute (NCI) | 2006-12-12 |
| Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma (NCT00418093) | Dana-Farber Cancer Institute | 2006-09-01 |
| Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer (NCT00466986) | Southeastern Gynecologic Oncology | 2005-11-01 |
| Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer (NCT00314678) | John P. Fruehauf | 2005-09-01 |
| Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer (NCT00489359) | Eli Lilly and Company | 2005-07-01 |
| Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy (NCT00109096) | Eli Lilly and Company | 2005-06-01 |
| PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer (NCT00059618) | M.D. Anderson Cancer Center | 2003-04-01 |
| Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma (NCT00226915) | Japanese Gynecologic Oncology Group | 2003-04-01 |
| Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma (NCT00157560) | Massachusetts General Hospital | 2000-12-01 |